Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy-Reference-Cited by-同舟云学术

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy

Published:2021-02 Issue:1 Volume:6 Page:100034
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Ganzinelli M.,Linardou H.,Alvisi M.F.,Caiola E.,Lo Russo G.,Cecere F.L.,Bettini A.C.,Psyrri A.,Milella M.,Rulli E.,Fabbri A.,De Maglie M.,Romanelli P.,Murray S.,Broggini M.,Marabese M.,Garassino M.C.

Funder

Transcan Era-Net JTC-2011

AIRC

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out;Proto;Cancer Treat Rev,2019

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy;Makovec;Radiol Oncol,2019

4. Direct cellular responses to platinum-induced DNA damage;Jung;Chem Rev,2007

5. The resurgence of platinum-based cancer chemotherapy;Kelland;Nat Rev Cancer,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

2. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

3. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-05-21